AC Immune (ACIU) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | AC Immune SA : Jefferies Cuts Target Price to $7 From $8
ReutersJan 8 00:36 ET
US Penny Stocks Spotlight: AC Immune And Two Others To Consider
Yahoo FinanceJan 2 19:07 ET
AC Immune Announces Key Executive Promotions to Strengthen R&D Leadership
TipRanksDec 18, 2024 17:50 ET
AC Immune Announces Promising Safety Data for Down Syndrome Therapy
TipRanksDec 10, 2024 08:46 ET
Express News | AC Immune SA - ACI-24.060 Safe and Well Tolerated in Down Syndrome Patients
ReutersDec 10, 2024 07:00 ET
AC Immune Reports Interim Safety Data From Phase 1b/2 ABATE Trial of ACI-24.060 in Down Syndrome
AC ImmuneDec 10, 2024 00:00 ET

Comments

Big Potato

Feb 13 14:33

$AC Immune (ACIU.US)$ zacks number 1

Trytosaveabit

Dec 10, 2024 06:03

Update

$AC Immune (ACIU.US)$ Reuters· 3 mins ago
AC Immune SA - ACI-24.060 Safe and Well Tolerated in Down Syndrome Patients

Trytosaveabit

Nov 14, 2024 06:03

Update

$AC Immune (ACIU.US)$ Reuters· 2 mins ago
AC Immune Reports Positive Interim Results From Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

Jaguar8

Nov 14, 2024 06:02

NEWS

$AC Immune (ACIU.US)$
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
AC Immune (NASDAQ: ACIU) announced positive interim results from its Phase 2 VacSYn trial of ACI-7104.056, an active immunotherapy for early Parkinson's disease.
The treatment showed significant efficacy, inducing anti-a-synuclein antibody levels 16-fold higherthan placebo after 3 immunizations, with a 100% patient response rate.
The trial rep...

amiable Hedgehog_758

Sep 17, 2024 06:34

$AC Immune (ACIU.US)$
AC Immune Reaches Key Milestone in Alzheimer's Immunotherapy, Receives CHF 24.6M
Benzinga· 10 mins ago5mins
AC Immune (ACIU.US)
3.270
3.530
+2.83%
+7.95%
AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that it will receive the second ReTain-related milestone payment (CHF 24.6 million) under its agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson co...

1

ACIU AC Immune

Trade Overview

Capital Trend

News

Comments

Trending Stocks